Suchergebnisse - "Patel, Kashyap"

PubPharm (7)

1

Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development

enthalten in: CPT: pharmacometrics & systems pharmacology | 2024

von Lu, Y. | Liang, S. | Hong, Y. | +9

2

Activation of ErbB2- ErbB3 signaling pathway supports potential therapeutic activity of ErbB inhibitors in AT/RT

enthalten in: Journal of neuro-oncology | 2014

von Sredni, S. | Patel, K. | D'Almeida Costa, F. | +2

CommentOn: J Neurooncol. 2013 Sep;114(2):173-9. - PMID 23836190

3

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma

enthalten in: Cancer chemotherapy and pharmacology | 2011

von Abou-Alfa, G. | Chan, S. | Lin, C. | +9

4

A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity

enthalten in: Cancer chemotherapy and pharmacology | 2011

von Patel, K. | Choy, S. | Hicks, K. | +3

5

Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice

enthalten in: Cancer chemotherapy and pharmacology | 2011

von Gu, Y. | Guise, C. | Patel, K. | +8

ErratumIn: Cancer Chemother Pharmacol. 2011 May;67(5):1209 Lie, Jie [corrected to Li, Jie]

6

Oxygen dependence and extravascular transport of hypoxia-activated prodrugs : comparison of the dinitrobenzamide mustard PR-104A and tirapazamine

enthalten in: International journal of radiation oncology, biology, physics | 2007

von Hicks, K. | Myint, H. | Patterson, A. | +4

7

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2007

von Patterson, A. | Ferry, D. | Edmunds, S. | +10

1
[1]